Senseonics states 365-day CGM to double 2025 sales

Senseonics aims to double its user base and sales in 2025 with the launch of its 365-day continuous glucose monitor (CGM) implant. Currently a minor player with projected sales of $22-24 million this year, Senseonics sees the longer-lasting sensor, requiring less frequent calibration, as a key growth driver.

The company is discussing integration of its Eversense CGM with insulin pump manufacturers without a finalized timeline. In 2024, Senseonics plans to more than double U.S. new patient starts and increase global installations by 50% based on its current 180-day Eversense CGM.

The 365-day sensor is set for a U.S. launch in Q4. Consumer research favors its reduced calibration frequency; while the 180-day version requires twice-daily calibration, the 365-day sensor needs weekly calibration.

Senseonics expects global users to grow from 6,000 in 2024 to 12,000 in 2025, leveraging reduced calibration to facilitate device integration efforts. Eversense competes with Abbott and Dexcom in the CGM market.